About 20% of breast cancer patients have HER-2 overexpression, and despite recent advances in the development of anti-HER2 drugs, these tumors still exhibit a high proliferation rate and have a poor prognosis (73). This evidence concerns the gene ERBB2 and breast carcinoma.